Background-The pulmonary circulation is an important site for the production and clearance of endothelin (ET)-1, a potent vasoactive and mitogenic peptide. Increased plasma ET-1 levels are observed in pulmonary arterial hypertension (PHT) and may contribute to the regulation of pulmonary vascular resistance, as well as to proliferative changes in the pulmonary vascular bed. Methods and Results-We prospectively assessed changes in plasma big ET-1 levels and changes in ET A and ET B receptor gene expression in 14 consecutive patients undergoing pulmonary thromboendarterectomy for thromboembolic PHT. Plasma big ET-1 levels were higher in patients with PHT (median, 2.2 pg/mL; 25th to 75th percentile, 1.5 to 3.0 pg/mL) compared with age-matched controls (median, 1.2 pg/mL; 25th to 75th percentile, 1.0 to 1.4 pg/mL; Pϭ0.002). In addition to increased plasma big ET-1 levels, selective upregulation of ET B receptor mRNA transcripts and immunoreactive protein in the pulmonary artery was observed in the patients; however, ET A receptor gene expression was unaffected. Conclusions-These data suggest that changes in the ET signaling system in PHT caused by thromboembolic disease are not limited to an increased production of ET-1: they also affect ET receptor gene expression.
ndothelial mediators, most notably nitric oxide and endothelin (ET)-1, are now widely recognized as exerting potent effects on the cardiovascular system. 1,2 Impaired release of endothelial-dependent dilators such as prostaglandin I 2 has been documented in pulmonary arterial hypertension (PHT), while the release of endothelial-dependent constrictors such as thromboxane A 2 is augmented simultaneously. 3 Similarly, circulating levels of ET-1 are increased in various forms of PHT; these levels correlate with disease severity. 4, 5 The ET-1 gene is translated to a 203 amino acid precursor, which is then cleaved to form big ET-1. Big ET-1 is subsequently cleaved by the ET-converting enzyme into functional ET-1.
Two different ET receptors (ET A and ET B ) that mediate the effects of ET-1 have been cloned. 6, 7 ET A receptors are located on smooth muscle cells, where they mediate vasoconstriction; ET B receptors are found on both endothelial and smooth muscle cells, where they may mediate vasodilation or vasoconstriction. 1, 2 In addition, pulmonary ET B receptors reflect the predominant site for the clearance of circulating ET-1; these receptors are responsible for the removal of Ϸ50% of plasma ET-1 during pulmonary transit. 8 Thus, changes in the ratio of ET A to ET B receptor subtypes in the pulmonary vascular bed may significantly affect the functional response to ET-1, which is locally produced in pulmonary hypertension. 9, 10 Consistent with this concept, disruption of the ET B gene in rats was paralleled by higher plasma ET-1 levels and higher resting pulmonary vascular tone. 11 The objective of the present study was to assess plasma big ET-1 levels in patients undergoing pulmonary thromboendarterectomy (PTE) for thromboembolic PHT, along with changes in ET receptor gene expression in pulmonary artery biopsies obtained during surgery.
Methods

Patient Populations
Fourteen consecutive patients (6 men and 8 women aged a median of 58 years [25th to 75th percentile, 51 to 62 years]) who were undergoing PTE for PHT due to recurrent thromboembolism were enrolled after obtaining consent according to the Declaration of Helsinki. A preoperative mean pulmonary arterial pressure of 45 mm Hg (25th to 75th percentile, 44 to 53 mm Hg) and a resistance of 891 dynes · s -1 · cm -5 (25th to 75th percentile, 773 to 1369 dynes · s -1 · cm -5 ) were documented in these patients before surgery. Fourteen patients without a history of PHT who were undergoing cardiac surgery served as controls for plasma big ET-1 measurements. Samples were obtained from the radial artery using withdrawal systems containing ethylenediaminetetraacetic acid (Sarstedt). Plasma was stored at Ϫ80°C until analysis. Tissue samples obtained from the pulmonary arteries of 5 lung donors in whom PHT was excluded and from 14 patients undergoing PTE were used for reverse-transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry.
Measurement of Plasma Big ET-1
Plasma levels of big ET-1 were measured by means of an immunoassay using polyclonal capture and monoclonal detection antibodies highly specific for human big ET-1, with a detection limit of 0.1 pg/mL (Big ET-1 enzymatic immunoassay, Biomedica).
RNA Isolation and RT-PCR
RNA was prepared from 10 mg of pulmonary tissue, as described previously. 12 A total of 1 g of total RNA was reverse-transcribed after denaturation in a mixture of 1ϫPCR buffer, 5 mmol/L MgCl 2 , 2.5 U/L reverse transcriptase, 1 U/L RNase inhibitor, 2.5 mol/L random hexamer, and 1 mmol/L each dNTP. After an initial 10-minute incubation step at 20°C, reverse transcription was carried out for 15 minutes at 42°C, followed by 5 minutes of denaturation at 99°C. The following primers (MWG Biotech) were used to amplify a 302-bp ET A receptor or a 428-bp ET B receptor fragment: 5Ј-tgg cct ttt gat cac aat gac ttt-3Ј (ET A sense); 5Ј-ttt gat gtg gca ttg agc ata cag gtt-3Ј (ET A antisense); 5Ј-act ggc cat ttg gag ctg aga tgt-3Ј (ET B sense); and 5Ј-ctg cat gcc act ttt ctt tct caa-3Ј (ET B antisense). A total of 50 L of reaction mixture containing 1ϫPCR buffer, 2 mmol/L MgCl 2 , 10 L of cDNA as a template, 1 mol/L of each primer, and 2.5 U of Taq Polymerase (Gene Amp RNA PCR Kit, Perkin Elmer) were subjected to the PCR protocol. After an initial denaturation step at 95°C for 2 minutes, denaturation and annealing/elongation were performed at 95°C for 1 minute and 61°C for 1 minute, respectively. The reactions were repeated for 36 cycles. A 175-bp GAPDH fragment was amplified using 5Ј-cca tgg aga agg ctg ggg-3Ј as the sense primer and 5Ј-caa agt tgt cat gga tga cc-3Ј as the antisense primer. A total of 50 L of reaction mixture containing 1ϫPCR buffer, 2.0 mmol/L MgCl 2 , 4 L of cDNA as a template, 0.15 mol/L of each primer, 0.5 U of Taq Polymerase, and 1.25 mmol/L dNTP (Gene Amp RNA PCR Kit, Perkin Elmer) were subjected to the PCR protocol. After an initial denaturation step at 94°C for 3 minutes, denaturation, annealing, and elongation were performed at 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s, respectively. The reactions were repeated for 40 cycles. The PCR products were size-analyzed on a 1.5% agarose gel and stained with ethidium bromide. The reactions were within the linear range for all transcripts studied under these conditions.
Immunofluorescence Analysis of ET B Receptor Gene Expression
Indirect immunostaining was used to confirm the changes observed for RNA transcripts encoding for the ET B receptor subtype on the protein level and to assess the spatial expression pattern of ET B immunoreactive protein using a sheep anti-rat ET B antibody (Biotrend) that cross-reacts with the human ET B protein. After the blockade of unspecific binding sites, sections were incubated overnight with the primary antibody (dilution 1:50) at room temperature. As a secondary antibody, a biotinylated anti-sheep antibody (dilution 1:200) was used; it was detected by fluorescence microscopy after incubation with a streptavidin-Texas red conjugate.
Statistics
All data are reported as median and interquartile range. The Mann-Whitney U-test was used to compare control and PHT patient populations. Densitometric values of the RT-PCR gel were used for statistical comparison, although these results are reported as x-fold induction over control. PϽ0.05 was considered significant.
Results
Big ET-1 Concentrations in Patients Suffering From Severe Thromboembolic PHT
Systemic big ET-1 levels in plasma obtained from patients undergoing PTE (median, 2.2 pg/mL; range, 1.5 to 3.0 pg/mL) were significantly higher than concentrations observed in the plasma of control subjects undergoing coronary bypass grafting or aortic arch repair (median, 1.2 pg/mL; range, 1.0 to 1.4 pg/mL; Pϭ0.002).
Gene Expression of ET A and ET B in Severe PHT
mRNA expression for ET A receptors was comparable in the pulmonary arteries obtained from patients undergoing PTE and from donor lungs. In contrast, steady-state transcripts encoding for the ET B receptor subtype were selectively increased in samples obtained from patients with PHT over steady-state mRNA levels in tissue from harvested donor lungs (Figure 1) .
Increased gene expression of the ET B receptor subtype observed on the mRNA transcript level was confirmed on the protein level. ET B immunoreactive protein was not confined to the endothelium but was primarily observed in the hyperplastic media of pulmonary arterial tissue of the patients undergoing PTE (Figure 2) .
Discussion
In the present study, we investigated changes in the ET signaling system in patients undergoing PTE for severe thromboembolic pulmonary hypertension. Although increased systemic levels of ET-1 have been documented in PHT of various origins 4, 5 and are confirmed in our patient population on the level of the precursor big ET-1, little is known about changes in the expression of ET receptors. While steady-state levels of mRNA encoding for ET A receptors were unaffected in pulmonary arterial tissue, a significant increase of transcripts encoding the ET B receptor was observed in severe PHT. Although the increase of ET-1, which correlates with disease severity in PHT, has been suggested to contribute to the development of PHT and the structural remodeling of the pulmonary circulation, 1,2,4,5 the receptors mediating the hemodynamic and fibrogenic effects of ET-1 are unclear.
Accumulating evidence suggests that ET A receptors mediate vasoconstriction and proliferation, whereas ET B receptors primarily account for the clearance of ET-1, the release of vasodilators, and the inhibition of ET-converting enzyme. 2 In particular, the dichotomous role of the ET B receptor subtype has been emphasized lately and has sustained a discussion regarding the use of nonselective as opposed to ET A -specific antagonists for clinical use. 2, 13, 14 With respect to the latter, a recent double-blind, placebo-controlled study confirmed the therapeutic potential of the dual ET receptor antagonist bosentan, which improved pulmonary hemodynamics and exercise capacity. 14 However, on the basis of an increasing body of experimental evidence, ET A -selective antagonists may be superior to nonselective antagonists due to the beneficial effects of ET B stimulation. 13, 14 Upregulation of ET B gene expression with PHT, as observed in the present study, can be predominantly found in the hyperplastic media of pulmonary arterial biopsies. The relative contribution of ET B receptors expressed in the hyperplastic media for mediating effects other than vasomotion, most notably fibrogenesis or clearance of circulating ET-1 in human cardiovascular disease states, is largely speculative. Nevertheless, recent experimental data with pharmacological blockade of the ET B receptor subtype or targeting the ET B gene in rats suggest that stimulation of the ET B receptor has a net protective effect mediating vasodilation and clearance of ET-1 from the circulation. 11 In summary, our data demonstrate that changes in the ET signaling system are not limited to the increased production of the agonist ET-1, but also affect ET B receptor gene expression. These results may have an impact on clinical trials using either nonselective or ET A -selective antagonists such as bosentan or sitaxsentan, respectively. 
